U.S. sales of the treatment ... accounting for 47 percent of the global market. SK Biopharm stated that the two companies have secured the funding to develop and operate the joint venture for ...
SEOUL, Jan. 15 (Yonhap) -- SK Biopharmaceuticals Co. (SK Biopharm), a biopharmaceutical arm of SK Group, will establish a joint venture with ... for remote epilepsy treatment is expected to ...